Nicotra M R, Nisticò P, Mangoni A, Di Filippo F, Marincola F M, Natali P G
Regina Elena Cancer Institute, Rome, Italy.
J Immunother. 1997 Nov;20(6):466-9. doi: 10.1097/00002371-199711000-00006.
The human immune repertoire appears to be capable of recognizing normal antigens expressed by tumor cells. Among these antigens, those of differentiation, characterized by a restricted tissue expression, could be of clinical interest since they may represent a target for immunotherapeutic protocols. In this context we have evaluated, in benign and malignant lesions of the melanocytic lineage, the expression of the Melan-A/MART-1 antigen, which has been shown to be recognized by T cells, of HLA-A2 melanoma patients. The immunohistochemical analysis conducted with a Melan-A/MART-1 monoclonal antibody demonstrated that the antigen expression does not correlate with transformation or tumor progression. At variable levels Melan-A/MART-1, differently from other differentiation antigens, is homogeneously expressed by multiple autologous metastases and by melanoma metastases at different body sites. This tissue distribution adds further biological support to the ongoing use of Melan-A/MART-1-related peptides in active immunotherapy.
人类免疫库似乎能够识别肿瘤细胞表达的正常抗原。在这些抗原中，那些具有组织表达受限特征的分化抗原可能具有临床意义，因为它们可能代表免疫治疗方案的靶点。在此背景下，我们评估了HLA - A2黑色素瘤患者黑素细胞谱系的良性和恶性病变中Melan - A/MART - 1抗原的表达，该抗原已被证明能被T细胞识别。用Melan - A/MART - 1单克隆抗体进行的免疫组织化学分析表明，抗原表达与转化或肿瘤进展无关。与其他分化抗原不同，Melan - A/MART - 1在不同水平上由多个自体转移灶以及不同身体部位的黑色素瘤转移灶均匀表达。这种组织分布为在主动免疫治疗中持续使用Melan - A/MART - 1相关肽提供了进一步的生物学支持。
